Five-year prospective study of clinical EEG, neuropsychological, and demographic risk variables for persistent tardive dyskinesia.
Struve
F A
FA
D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects*; D002493:Central Nervous System Diseases / Q000150:complications; D004409:Dyskinesia, Drug-Induced / Q000150:complications / Q000453:epidemiology*; D004565:Electroconvulsive Therapy; D004569:Electroencephalography; D005260:Female; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008297:Male; D011446:Prospective Studies; D011581:Psychological Tests; D012306:Risk
D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D008094:Lithium